Donor examination activities began on Friday, October 16 at the FDA and CLIA-certified testing lab; Data to also be used for EU CE marking and emergency approval in The countries of the Russian Federation
LOS ANGELES, CA / ACCESSWIRE / October 19, 2020 / Decision Diagnostics Corp. (OTC PINK: DECN) www. decisiondiagnostics. co, the world’s leading manufacturer and distributor of diabetic control strips designed to work on legacy glucometers through its subsidiary Pharma Tech Solutions, Inc. , today announced the start of its donor examination as a precursor to its FDA USA, EU CE Mark and the Russian Federation of its Genviro!Saliva Swift Kit for Covid-19. The donor examination and controls imaginable under FDA rules will be performed through the company’s FDA and CLIA certified check spouse in the United States.
“Our plans are in line with the objectives of the us FDA’s fourth quarter filings, the EU CE marking and the Russian Federation. The donor is the launch pad for the paintings you want to make and the initial paintings are encouraging and exceed our expectations,” said Keith, Berlin’s chief executive.
“When the existing series of controls is completed, there will be 3 sets of controls that we hope to download FDA approval and allow US professionals to do so. But it’s not the first time Be sure that GenViro results are as accurate as possible. CE marking of the EU and applications of the Russian Federation, although they belong to an elegance of emergency presentation similar to that of FDA guidelines, adhere to a different, less stringent and hopefully faster sign of approval, which is precisely what we have been looking for with Genviro!Saliva Swift Kit. “
While the company’s initial submission to the U. S. FDA in April involved its finger-of-blood editing of the GenViro kit!Swift, new advances have led him to the existing method of saliva that is less invasive and, according to recent studies, more accurate.
https://time. com/5891887/covid-19-saliva-spit-test/
ABOUT DECISION DIAGNOSTICS CORP
The company’s new GenViro!™ products designed to verify Covid-19 are not yet available in the US. But it’s not the first time Or Puerto Rico, but emergency exemptions (U. S. ) are ongoing with the U. S. FDA. But it’s not the first time And more presentations will be made in the near future. The company has also signed an agreement with an FDA-qualified check spouse and U. S. CLIA. But it’s not the first time To conduct verifications in accordance with existing FDA rules and continues to await FDA approval from our U. S. FDA. But it’s not the first time
The same knowledge that will be produced through the new company spouse will be used for submissions to the EU and the Russian Federation. We will also use the knowledge provided through our Korean spouse R
The company continues to recruit and conform to programs of potential domestic and foreign distributors. Inquiries can be directed to info@decisiondiagnostics. co.
Forward-looking statements:
CONTACT INFORMATION:
OTHER CONTACT INFORMATION:
SOURCE: Decision Diagnostics Corp.